Core Points - Quest PharmaTech Inc. held its annual general meeting on August 25, 2025, where four directors were re-elected to the Board of Directors [1] - The company reported that approximately 50,288,000 shares were voted, representing about 29.7% of the eligible shares [2] - Quest granted 1,900,000 stock options to Directors and Officers at an exercise price of $0.05 per share, expiring in 10 years, pending TSX Venture Exchange approval [3] Company Overview - Quest PharmaTech Inc. is a Canadian biopharmaceutical company focused on developing products to enhance quality of life through proprietary technologies and investee companies [4] - The company is developing MAb-AR9.6, a theranostic agent targeting MUC16 for cancer, which is currently in late preclinical stage development [4] - Quest holds a 42.5% interest in OncoQuest Inc., which sold its immunotherapy technology assets in April 2020, and a 23% interest in OncoVent, a joint venture in China focused on antibody-based immunotherapeutic products for cancer [4]

Core Viewpoint - Quest PharmaTech Inc. opposes the acquisition of a controlling interest in AdBioTech by OQPBIOM Inc. and was not consulted prior to this decision, raising concerns about the implications for funding and the advancement of its immunotherapy assets [1][3]. Group 1: Company Background - Quest PharmaTech Inc. is a Canadian biopharmaceutical company focused on developing products to enhance quality of life [4]. - The company holds a 42.5% ownership interest in OncoQuest Inc. and a 23% ownership interest in OncoVent, which is involved in developing antibody-based immunotherapeutic products for cancer [4]. - Quest is also developing proprietary MAb AR 9.6, which targets truncated MUC16 as theranostic agents for cancer and is currently in the late preclinical stage [4]. Group 2: Recent Developments - As of June 2, 2025, Quest acquired a 26.25% share ownership interest in OQPBIOM Inc., becoming its largest shareholder [2]. - OQPBIOM Inc. was established to conduct clinical trials for oregovomab, a novel ovarian cancer drug candidate developed by OncoQuest Inc. [2]. - Quest's CEO, Dr. Madi Madiyalakan, expressed that the company was not informed about OQM's acquisition strategy and believes it is not in the best interest of OQM or its shareholders [3].

EDMONTON, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today provided a corporate update and announced that it has filed its annual audited financial statements for the year ended January 31, 2025, Management’s Discussion and Analysis and related filings on SEDAR+ (www.sedarplus.ca). The Company report ...